Search Results - "Garcia, Linta"

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK -rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study by Gadgeel, Shirish M, MD, Gandhi, Leena, MD, Riely, Gregory J, MD, Chiappori, Alberto A, MD, West, Howard L, MD, Azada, Michele C, MPH, Morcos, Peter N, PharmD, Lee, Ruey-Min, MD, Garcia, Linta, PharmD, Yu, Li, PhD, Boisserie, Frederic, MSc, Di Laurenzio, Laura, PhD, Golding, Sophie, MSc, Sato, Jotaro, MS, Yokoyama, Shumpei, MS, Tanaka, Tomohiro, MS, Ou, Sai-Hong Ignatius, Dr

“…Summary Background Patients with non-small-cell lung cancer (NSCLC) and ALK rearrangements generally have a progression-free survival of 8–11 months while on…”
Get full text

P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST‐HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY by Kim, Won‐Seog, Shortt, Jake, Luigi Zinzani, Pier, Mikhaylova, Natalya, Marin‐Niebla, Ana, Radeski, Dejan, Ribrag, Vincent, Domingo Domènech, Eva, Sawas, Ahmed, Alexis, Karenza, Emig, Michael, Garcia, Linta, Overesch, Andre, Pietzko, Kerstin, Horwitz, Steven

Get full text

A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma or transformed mycosis fungoides: The REDIRECT study design and rationale by Choe-Juliak, Cassandra, Alexis, Karenza M., Schwarz, Sylvia, Garcia, Linta, Sawas, Ahmed

“…Abstract only TPS3148 Background: AFM13 is a tetravalent, bispecific (anti-CD30/anti-CD16A) recombinant antibody being developed for the treatment of…”
Get full text

A Phase 2 study of acimtamig (AFM13) in patients with CD30-positive, relapsed or refractory peripheral T-cell lymphomas by Kim, Won Seog, Shortt, Jake, Zinzani, Pier Luigi, Mikhailova, Natalia, Radeski, Dejan, Ribrag, Vincent, Domingo Domenech, Eva, Sawas, Ahmed, Alexis, Karenza, Emig, Michael, Elbadri, Riham, Hajela, Pallavi, Ravenstijn, Paulien, Pinto, Sheena, Garcia, Linta, Overesch, Andre, Pietzko, Kerstin, Horwitz, Steven

“…Background: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. Materials…”
Get full text

Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL) by Kim, Won Seog, Shortt, Jake, Zinzani, Pier Luigi, Mikhaylova, Natalya, Marin-Niebla, Ana, Radeski, Dejan, Ribrag, Vincent, Domenech, Eva Domingo, Sawas, Ahmed, Alexis, Karenza, Emig, Michael, Garcia, Linta, Overesch, Andre, Pietzko, Kerstin, Horwitz, Steven

“…PTCLs are aggressive hematologic malignancies often with poor prognoses; for patients with R/R PTCL there is no standard-of-care therapy and novel treatments…”
Get full text

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistantALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study by Gadgeel, Shirish M, Gandhi, Leena, Riely, Gregory J, Chiappori, Alberto A, West, Howard L, Azada, Michele C, Morcos, Peter N, Lee, Ruey-Min, Garcia, Linta, Yu, Li, Boisserie, Frederic, Di Laurenzio, Laura, Golding, Sophie, Sato, Jotaro, Yokoyama, Shumpei, Tanaka, Tomohiro, Ou, Sai-Hong Ignatius

“…Patients with non-small-cell lung cancer (NSCLC) andALKrearrangements generally have a progression-free survival of 8-11 months while on treatment with the ALK…”
Get full text